A
Antonio Craxì
Researcher at University of Palermo
Publications - 699
Citations - 44773
Antonio Craxì is an academic researcher from University of Palermo. The author has contributed to research in topics: Hepatitis C & Cirrhosis. The author has an hindex of 86, co-authored 659 publications receiving 39463 citations. Previous affiliations of Antonio Craxì include University of Pavia & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.
Salvatore Petta,Giuseppe Cabibbo,Marco Barbara,Simona Attardo,Luigi Bucci,Fabio Farinati,E.G. Giannini,Francesco Tovoli,Francesca Ciccarese,G.L. Rapaccini,M. Di Marco,Eugenio Caturelli,Marco Zoli,Franco Borzio,Rodolfo Sacco,Roberto Virdone,Fabio Marra,Martina Felder,Filomena Morisco,L. Benvegnù,Antonio Gasbarrini,Gianluca Svegliati-Baroni,Francesco Giuseppe Foschi,Andrea Olivani,Alberto Masotto,G. Nardone,Antonio Colecchia,Marcello Persico,V. Boccaccio,Antonio Craxì,Savino Bruno,Franco Trevisani,Calogero Cammà +32 more
TL;DR: In HCV‐infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)‐based or IFN‐free regimens on H CC recurrence remain unclear.
Journal ArticleDOI
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease
Salvatore Petta,Oreste Marrone,Daniele Torres,Maria Buttacavoli,Calogero Cammà,Vito Di Marco,Anna Licata,Anna Lo Bue,Gaspare Parrinello,Antonio Pinto,Adriana Salvaggio,Antonino Tuttolomondo,Antonio Craxì,Maria R. Bonsignore +13 more
TL;DR: To consider sleep disordered breathing as a potential additional therapeutic target in severe NAFLD patients with chronically elevated ALT at low prevalence of morbid obesity, OSA was highly prevalent and indexes of SaO2 resulted independently associated with severity of liver fibrosis and carotid atherosclerosis.
Journal ArticleDOI
Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST expert opinion meeting
Daniele Prati,Antonio Gasbarrini,Francesco Mazzotta,Evangelista Sagnelli,Giampiero Carosi,N. Abrescia,Alfredo Alberti,Silvia Ambu,P. Andreone,Angelo Andriulli,Mario Angelico,Giorgio Antonucci,Antonio Ascione,Luca S. Belli,Raffaele Bruno,Savino Bruno,Patrizia Burra,Calogero Cammà,Nicola Caporaso,Giuseppe Cariti,Umberto Cillo,Nicola Coppola,Antonio Craxì,Andrea De Luca,Eleonora De Martin,Vito Di Marco,Stefano Fagiuoli,Carlo Ferrari,Giovanni Battista Gaeta,Massimo Galli,Antonio Grieco,Paolo Grossi,Anna Licata,Ivana Maida,Alessandra Mangia,N. Marino,Renato Maserati,Gabriele Missale,Mario U. Mondelli,Paola Nasta,Grazia Anna Niro,Marcello Persico,Enzo Petrelli,Antonio Picciotto,Fabio Piscaglia,Teresa Pollicino,Claudio Puoti,Massimo Puoti,Giovanni Raimondo,Maria Grazia Rumi,Teresa Santantonio,Antonina Smedile,Giovanni Squadrito,Gianluca Svegliati Baroni,Gloria Taliani,Marcello Tavio,Mario Toti,Ferruccio Bonino,Maurizia Rossana Brunetto,Bruno Cacopardo,Marcello Caremani,Roberto Cauda,Massimo Colombo,Giovanni Di Perri,Francesca Donato,Patrizia Farci,Giovanna Fattovich,Gaetano Filice,Florio Ghinelli,Vincenzo Guadagnino,Adriano Lazzarin,Massimo Levrero,Giuseppe Licata,Anna Orani,Amerigo Paffetti,Giuseppe Pastore,Felice Piccinino,Eligio Pizzigallo,Patrizia Pontisso,V. Portelli,Mario Rizzetto,Alessandro Rossi,Tommaso Stroffolini,Enzo Ubaldi,Teresa Santantanio,G. Antonucci +85 more
TL;DR: Recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies, say there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response.
Journal ArticleDOI
Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association.
Salvatore Petta,Antonio Craxì +1 more
TL;DR: A number of studies suggest that these approaches improve IR and reduce steatosis, necroinflammation and fibrosis and a potential role of these therapeutic strategies in the prevention of hepatocarcinogenesis can be envisaged.
Journal ArticleDOI
Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial
Fred Poordad,Eric Lawitz,K. Rajender Reddy,Nezam H. Afdhal,Christophe Hézode,Stefan Zeuzem,Samuel S. Lee,Jose Luis Calleja,Robert S. Brown,Antonio Craxì,Heiner Wedemeyer,L. Nyberg,David R. Nelson,Lorenzo Rossaro,Luis A. Balart,Timothy R. Morgan,Bruce R. Bacon,Steven L. Flamm,Kris V. Kowdley,W. Deng,Kenneth Koury,Lisa D. Pedicone,Frank J. Dutko,Margaret Burroughs,Katia Alves,Janice Wahl,Clifford A. Brass,Janice K. Albrecht,Mark S. Sulkowski +28 more
TL;DR: Reduction of ribavirin dosage can be the primary approach for management of anemia in patients receiving peginterferon, Ribavirin, and boceprevir for HCV infection, and it is important that the patient receives at least 50% of the total amount of ribvirin assigned by response-guided therapy.